Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Taizhou Enze Medical Center (Group) is currently prosecuting a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio contains 1 pending office action, which is assigned to HOWARD, ZACHARY C. As the busiest examiner for the company, HOWARD, ZACHARY C is managing 1 pending action, which accounts for the entire active workload. This prosecution is centralized within 1 distinct examiner and 1 distinct art unit, reflecting a focused technical scope.
The 1 pending office action in Biotechnology & Pharmaceuticals indicates a specific point of engagement with the USPTO. Since there is 1 distinct art unit involved, the company's current applications are being reviewed within a single specialized group. The busiest examiner, HOWARD, ZACHARY C, holds 1 pending action, matching the total number of pending office actions for the portfolio. This alignment means the company's current outcomes in this technology area are tied to the 1 distinct examiner currently assigned.
Practitioners should note that the 1 distinct examiner and 1 distinct art unit provide a singular channel for the company's current intellectual property efforts. With 1 pending office action, there is no current distribution of work across different examiners or units. This concentration under HOWARD, ZACHARY C underscores the importance of this examiner's specific review process for the 1 pending office action currently in the pipeline.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOWARD, ZACHARY C | 1 | 63.9% | +37.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18573956 | MONOCLONAL ANTIBODY AGAINST HLA-G1, -G2, -G5 AND HLA-G6 ISOFORMS AND USE THEREOF | HOWARD, ZACHARY C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18573956 | MONOCLONAL ANTIBODY AGAINST HLA-G1, -G2, -G5 AND HLA-G6 ISOFORMS AND USE THEREOF | HOWARD, ZACHARY C | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18573956 | MONOCLONAL ANTIBODY AGAINST HLA-G1, -G2, -G5 AND HLA-G6 ISOFORMS AND USE THEREOF | HOWARD, ZACHARY C | 1674 | §101§112 | Non-Final OA | — | Pending | Dec 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTaizhou Enze Medical Center (Group) has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Zachary C Howard has the most, with 1 of Taizhou Enze Medical Center (Group)'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
